Patients diagnosed with a type of brain tumour survived for longer when they were treated aggressively with surgery, radiation and chemotherapy. But far from suggesting that more treatment always leads to better survival, the study by UC San Francisco underscores the critical role of genomic profiling in diagnosing and grading brain tumours.
In the study, UCSF researchers followed 38 patients with a tumour type that was reclassified by the World Health Organisation in November 2021, from a grade 2 or 3 glioma, to a “glioblastoma, IDH-wildtype, CNS WHO grade 4,” based on its molecular features.
The new more accurate diagnosis comes from genomic profiling in which the DNA alterations that drive tumour growth are identified. The previous diagnosis was determined by traditional microscopic comparisons between cancer cells and normal cells.
All patients underwent genomic sequencing using the UCSF500 Cancer Gene Panel and were offered treatment consistent with a conventional glioblastoma, the deadliest and most common adult brain tumour. The length of their survival was compared with a retrospective cohort of 130 patients with the same tumor type, whose treatment regimens were more conservative, in line with the previous tumour classification.
The first group of patients survived an average of 24 months, while the second group survived an average of 16 months, the researchers reported in their study, appearing in the online issue of Neuro-Oncology, and publishing in the journal’s print version later this year.
“The study shows that genomic profiling resulted in more aggressive patient management that ultimately led to improved clinical outcomes, compared to the biologically matched historical patient cohort,” said senior author, David Solomon, MD, PhD, assistant professor in the UCSF Department of Pathology, investigator at the UCSF Brain Tumour Center, and a principal investigator of the UCSF Glioblastoma Precision Medicine Program.
Early/Evolving Glioblastoma May Have ‘Underlying Biologic Differences’
In studying the MRIs of the first group of patients, the researchers found that 33 of the 38 had imaging features suggestive of a lower-grade glioma, while the remaining five had imaging features suggestive of conventional glioblastoma, such as peripheral enhancement and dead tissue.
While both groups were histologically and molecularly indistinguishable, the first set, so-called early/evolving glioblastoma, may have “underlying biologic differences” in the immune micro-environment and an intact blood-brain barrier that may affect treatment efficacy.
The UCSF research was prompted by a landmark 2015 study by the Cancer Genome Atlas Research Network that performed genome-wide analyses on 293 grade 2 and 3 gliomas. The researchers identified a subset of patients, approximately one in five, who lacked an IDH mutation, a molecular biomarker known to be associated with better outcomes.
The genomic profile of this subset, which was categorised as IDH-wildtype glioma, mirrored that of the UCSF patients. The patients in this subset were on average 50 years old at diagnosis, about 5 to 10 years older than the patients with IDH-mutant gliomas.
“While these patients did not have the traditional histological hallmarks of conventional glioblastoma, they shared the same molecular features and had similar survival,” said Solomon, who has pioneered genomic profiling for diagnostic classification and treatment of brain tumours at UCSF since 2015, and has co-authored more than 50 publications on brain tumour molecular pathogenesis.
Study Solves Survival Mystery for Doctors Treating Lower-Grade Glioma
The results of this study not only led to the treatment objective of the UCSF study, but it also solved a conundrum that had bedevilled neuro-oncologists for years: why some grade 2 and 3 glioma patients progressed slowly and survived for several years, while others advanced rapidly and died within a year or two.
“Historically, we’ve relied on what pathologists see under the microscope to guide treatment, which can be subjective to the pathologist’s experience and the size of the sample collected from the neurosurgeon, said co-author Jennie Taylor, MD, MPH, a neuro-oncologist with the UCSF Department of Neurological Surgery who treats adult brain tumour patients.
“For patients with tumours that are not surgically accessible, this may mean under-sampling of a tumour, which could lead to a patient being misdiagnosed, under treated, and ineligible for clinical trial enrolment.”
Future research may further extend the survival of patients with IDH-wildtype glioblastoma, said Taylor, who is also affiliated with the UCSF Weill Institute for Neurosciences.
“Integrating genomic profiling into the pathology report (which takes a small quantity of brain tumour cells) means that doctors can be more confident in their treatment recommendations, enabling more patients to take part in clinical trials.”
When the UCSF500 Cancer Gene Panel was first implemented in 2015, around 5 to 10% of patients had to have their pathological diagnosis amended following genomic testing, Solomon said. In paediatrics, the figure was even higher, affecting six of the first 31 patients who were tested, according to a 2016 study.
Today, genomic sequencing is routinely carried out for all adult and paediatric brain tumours at UCSF to ensure accurate diagnosis and optimal care. It is usually covered by both private and public insurers.
A preliminary pathological diagnosis following microscopic review is made after tumour resection or biopsy. A final diagnosis integrating the molecular findings comes about three weeks later, but radiation or chemotherapy may be initiated earlier if recommended.
Sometimes the final diagnosis is sobering, and sometimes it is joyful, such as the child whose earlier microscopic evaluation had pointed towards a grade 4 tumour, which was corrected to grade 1 tumour after genomic testing, said Solomon.
“There’s no question that we need a definitive diagnosis to provide the most appropriate treatment plan. That might mean more treatment and it might mean less.”
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.